<DOC>
	<DOCNO>NCT01925950</DOCNO>
	<brief_summary>Use oral topically-active glucocorticoid limited side effect may control gastrointestinal inflammatory process GVHD minimize glucocorticoid exposure .</brief_summary>
	<brief_title>Study orBecÂ® Monotherapy Treatment Patients With Upper GI Symptoms Caused Chronic Graft Versus Host Disease ( GVHD )</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Receipt allogeneic hematopoietic cell transplant &gt; 100 day prior consent Documented cGVHD define NIH consensus criterion least one organ system GI tract ( example , cGVHD oral cavity would qualify criterion ) Endoscopic finding consistent GI GVHD Must able swallow tablet Must able read understand inform consent Adequate birth control method duration study &gt; 500 mL/day diarrhea 1 day within 3 day prior first dose study drug GI infection Multiorgan failure condition , opinion investigator , would compromise patient 's ability complete study . HIV seropositivity Pregnant nursing female Use investigational drug treat chronic GVHD within 28 day first dose study drug Evidence recurrent progress malignant disorder indication HCT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>BDP</keyword>
	<keyword>orBec</keyword>
	<keyword>GVHD</keyword>
	<keyword>beclomethasone dipropionate</keyword>
	<keyword>bone marrow transplant</keyword>
	<keyword>hematopoietic cell transplant</keyword>
	<keyword>HCT</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>marrow transplant</keyword>
	<keyword>SCT</keyword>
	<keyword>beclomethasone 17,21-dipropionate</keyword>
</DOC>